
Proacta delivers bioinformatics and commissioned software development to its clients.
proacta.plCrawled Nov 16, 2026
The reports provide insights into how various factors—such as lifestyle data, existing conditions, symptoms, diet, supplements, and medications—may influence health risks.
The project ‘Development of a platform for automated analysis of laboratory test results based on the Dbam o Siebie Smart LAB solution’ is funded under the National Recovery and Resilience Plan, Component D: Efficiency, Availability, and Quality of the Health Protection System, Investment D3.1.1: Comprehensive Development of Research in Medical and Health Sciences.
The Digital Breast Cancer Unit (DBCU) integrates clinical guidelines, medical knowledge, and patient data to support doctors in making more informed treatment decisions.
The platform enables personalized therapies by aligning treatments with individual patient needs using digital patient models.
The page discusses key IT trends for 2025 in an article published on PulsHR by the company’s president.
Proacta SA established a Medical Advisory Board to support the development of certified medical products and data/smart analysis solutions in healthcare.
Healthcare systems globally face challenges like rising patient numbers, doctor shortages, and increasing treatment costs.
Proacta SA’s Extraordinary General Meeting appointed a new three-year Supervisory Board from July 1, 2026, to June 30, 2029.
Proacta SA signed a letter of intent with VeritaMed Sp. z o.o. for a pilot implementation of the ‘Dbam o Siebie’ platform.
Proacta SA’s president, Paweł Ciesielka, spoke about AI-supported medicine and the company’s bioinformatics expertise in an interview with MamBiznes.pl.
Arkadiusz Zachwieja resigned as Proacta SA board member, effective December 23, 2024.
Proacta SA secured additional orders under a framework agreement with PKO Życie and PKO Towarzystwo Ubezpieczeń for IT specialists and system development.
Proacta SA signed a letter of intent with Szpital Czerniakowski Sp. z o.o. to create AI-driven medical data analysis solutions.
Proacta SA signed a framework agreement with Colway J. Zych N. Zych Spółka Jawna in Koleczkowo.
A medical project advanced to substantive evaluation in the 2024/ABM/06/KPO competition for medical device and diagnostic solutions.
Proacta SA specializes in bioinformatics and software development, combining IT with biology to advance medicine and natural sciences.
Early projects focused on genetic data analysis and mapping, accelerating biomedical research and therapy development.
The page provides information on corporate governance practices.
Proacta S.A. partners with Medincus to pilot its clinical and genetic data platform under a six-month agreement. The collaboration focuses on deploying the platform to integrate and analyze patient data for potential medical insights. Medincus, a hearing and speech center, will test the system’s capabilities in a real-world clinical setting.
Proacta provides AI and medical data analysis services to Ares Thera under a new framework agreement. The partnership supports Ares Thera’s product development, including validation and regulatory compliance. Proacta highlights rising demand for AI-driven projects integrating data, validation, and regulatory standards in healthcare and MedTech.
Proacta S.A. and PZU Zdrowie are piloting the **Dbam o Siebie Smart LAB** platform, a digital health tool designed for corporate and clinical applications. The Warsaw-based company specializes in healthcare technology solutions, expanding its reach through this collaboration. The pilot marks a step toward integrating AI-driven diagnostics into workplace and medical settings.
Proacta S.A. clarifies its cooperation agreement with PZU Zdrowie S.A. for a pilot deployment of the **Dbam o Siebie Smart LAB** technology. The company updates a prior regulatory filing to fully disclose the terms of the partnership. The agreement involves testing the smart lab solution in a controlled environment to assess its integration with PZU Zdrowie’s healthcare services.
Proacta S.A. creates a Medical Board to advance its certified medical device ecosystem. The bioinformatics firm, listed on NewConnect, focuses on healthcare solutions. The board aims to guide development within the medical device sector.